Dataset Information


Drug-Eluting Biodegradable Implants for the Sustained Release of Bisphosphonates.

ABSTRACT: Despite being one of the first-line treatments for osteoporosis, the bisphosphonate drug class exhibits an extremely low oral bioavailability (<1%) due to poor absorption from the gastrointestinal tract. To overcome this, and to explore the potential for sustained drug release, bioerodible poly(lactic acid) (PLA) and poly(D,L-lactide-co-glycolide) (PLGA) implants loaded with the bisphosphonate alendronate sodium (ALN) were prepared via hot-melt extrusion. The rate of drug release in vitro was modulated by tailoring the ratio of lactide to glycolide in the polymer and by altering the ALN-loading of the implants. All investigated implants exhibited sustained ALN release in vitro between 25 to 130 days, where implants of greater glycolide composition and higher ALN-loadings released ALN more rapidly. All PLGA implants demonstrated a sigmoidal release profile, characterised by an initial surface dissolution phase, followed by a period of zero-order drug diffusion, then relaxation or erosion of the polymer chains that caused accelerated release over the subsequent days. Contrastingly, the PLA implants demonstrated a logarithmic release profile, characterised by a gradual decrease in ALN release over time.

SUBMITTER: Dharmayanti C 

PROVIDER: S-EPMC7762379 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC6149750 | BioStudies
2019-01-01 | S-EPMC6680571 | BioStudies
1000-01-01 | S-EPMC6058690 | BioStudies
1000-01-01 | S-EPMC4076690 | BioStudies
2012-01-01 | S-EPMC3525582 | BioStudies
2016-01-01 | S-EPMC4681614 | BioStudies
2019-01-01 | S-EPMC6978636 | BioStudies
2016-01-01 | S-EPMC7335463 | BioStudies
2015-01-01 | S-EPMC4846283 | BioStudies
1000-01-01 | S-EPMC6058517 | BioStudies